Galafold

Shares of Amicus Therapeutics, Inc. (NASDAQ: FOLD) plunged more than 22 percent on news that the FDA seeks a pivotal "cross-over" study of Galafold (migalastat) in treatment-naive Fabry disease patients with gastrointestinal (GI) symptoms to approve the drug. FDA Requests Additional...

Bank of America's Peter Stapor initiated a Buy rating on Amicus Therapeutics, Inc. (NASDAQ: FOLD) with a price target of $10.00. The leading drug in the company's portfolio is migalastat (Galafold) for a rare disease (Fabry disease), which results in enzyme deficiency and can lead to organ failure...